Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I3C and Silibinin in Healthy Smokers
NCT03687073Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- Nov 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of indole-3-carbinol and silibinin in lung cancer, sponsored by Masonic Cancer Center. Started Nov 2018; status: completed.
02
Drugs
indole-3-carbinolsilibinin
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT03687073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03687073.